FindMyKOL

Naomi Fisher, MD

Enriched profile

Director of hypertension services and hypertension innovation · Brigham and Women's Hospital

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyEndocrinology, Diabetes & MetabolismFocusBlood Pressure and Hypertension Studies+4
Active KOLFindMyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding1998–2012

Naomi Fisher is Director of hypertension services and hypertension innovation at Brigham and Women's Hospital. OpenAlex indexes 187 publications with 8,351 citations (h-index 51); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 9 Nov 2026

Overview

Updated 20 Nov 2026

Naomi Fisher, MD, is Director of hypertension services and hypertension innovation at Brigham and Women's Hospital. The public record shows 187 publications with 8,351 citations (h-index 51), centered on Blood Pressure and Hypertension Studies, Renin-Angiotensin System Studies, Cardiovascular Health and Disease Prevention. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 7 companies, 6 NIH-funded awards (1998–2012).

  • Most recent indexed publication: 2026 · Hypertension (Dallas, Tex.
  • Top research focus: Blood Pressure and Hypertension Studies
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 20 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Hypertension6 trialsCardiovascular Diseases2 trialsVascular Diseases2 trialsAcromegalyAlzheimer's / DementiaAtrial FibrillationChronic Kidney DiseaseCoronary Artery Disease / ACSCOVID-19Cushing's SyndromeDyslipidemia / Lipid DisordersGoutHeart FailureObesitySubstance Use DisordersType 2 Diabetes

Research focus

OpenAlex concept fingerprint
Blood Pressure and Hypertension StudiesRenin-Angiotensin System StudiesCardiovascular Health and Disease PreventionHormonal Regulation and HypertensionRenal and Vascular Pathologies

Drugs & molecules

across trials, industry payments and publications
Xareltogeneric · RivaroxabanClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
ReCor Medical, Inc.Clinical trials2Industry payments22Medtronic, Inc.Clinical trials—Industry payments46Boston Scientific CorporationClinical trials—Industry payments3Aktiia SAClinical trials2Industry payments—Alnylam Pharmaceuticals Inc.Clinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2AstraZeneca UK LimitedClinical trials—Industry payments2Brigham and Women's HospitalClinical trials2Industry payments—Janssen Scientific Affairs, LLCClinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
187publications

Publications indexed by OpenAlex, matched via ORCID. 14 in PubMed. Counts exclude supporting files.

8,351citations

Citations across these publications.

51h-index

H-index from these publications. i10-index 97.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
6NIH grants · 1998–2012

Federally funded research awards.

View funding ↓

Contact

No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →

Clinical trials

Updated 9 Nov 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 9 Nov 2026

7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

  • Recor Medical Inc
    Program year202517 payments
    $18,411
  • Boston Scientific Corporation
    Program year20253 payments
    $6,033
  • AstraZeneca UK Limited
    Program year20241 payment
    $1,611
All 13 payment records: search, sort and filter.Explore →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    100%
    Calcium channel blocker32.3%
    Amlodipine Besylate70%Felodipine Er30%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)21.9%
    Irbesartan76%Olmesartan Medoxomil24%
    Part D<11 patients

    + 5 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 9 Nov 2026

6 NIH research awards on record, funded 1998–2012 per NIH RePORTER. The latest:

Congress activity

Updated 9 Nov 2026

8 congress contributions (2021–2026) across AHA, ESC, TCT (Transcatheter Cardiovascular Therapeutics) per OpenAlex. The most recent:

All 8 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles come from the meeting's own published program, matched through the same scorecard; a role we could not attribute with confidence is left off rather than guessed at.

Publications

Updated 9 Nov 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 9 Nov 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Norman K. Hollenberg61Benjamin M. Scirica28Gordon H. Williams28Christopher Paul Cannon24David Zelle22Ajay Jayant Kirtane19Deborah A. Price18Alexander J. Blood17Michel Azizi17Felix Mahfoud16Melvin David Lobo15Michael J. Bloch15Jorge Plutzky13Ozan Ünlü13Roland Erich Schmieder12John P. Forman12Kintur A. Sanghvi11Michael A. Weber11Philipp C. Lurz11Florian Rader11Candace K. McClure10Maria Cecilia Lansang10Kavishwar B. Wagholikar10Gary C. Curhan10Jan Basile10Manish Saxena10Michela R. Tucci10Joost Daemen10Radomir D Stevanovic9Hunter Nichols9Philippe Gosse9Lori M. Laffel9Chandan M. Devireddy9Yale L. Wang9Terry Levy8Thomas Andrew Gaziano8Marc R. Sapoval8Thomas M. Todoran8A.H. Jan Danser8Jeremy Sayer8

Online presence

Updated 9 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    audioboom.com/posts/7695105

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →audioboom.com ↗
  • Other

    catalyst.harvard.edu/about/all-people/naomi-fisher-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →catalyst.harvard.edu ↗
  • Other

    radcliffecardiology.com/authors/naomi-fisher

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →radcliffecardiology.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 9 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Pennsylvania

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →catalyst.harvard.edu ↗
  • Bachelor's degree

    Princeton University

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →catalyst.harvard.edu ↗

Secondary affiliations

appointments beyond the home institution
  • verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →catalyst.harvard.edu ↗
  • Harvard University
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.